GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunoCellular Therapeutics Ltd (FRA:KOL1) » Definitions » Short Interest

ImmunoCellular Therapeutics (FRA:KOL1) Short Interest


View and export this data going back to . Start your Free Trial

What is ImmunoCellular Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.


Competitive Comparison of ImmunoCellular Therapeutics's Short Interest

For the Biotechnology subindustry, ImmunoCellular Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ImmunoCellular Therapeutics's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmunoCellular Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where ImmunoCellular Therapeutics's Short Interest falls into.



ImmunoCellular Therapeutics (FRA:KOL1) Business Description

Traded in Other Exchanges
N/A
Address
136 Summit Avenue, Suite 100, Montvale, NJ, USA, 07645
EOM Pharmaceutical Holdings Inc is focused on developing novel immunomodulatory and retinal disease drug agents to address a range of inflammatory, viral, retinal, and other diseases. Its product candidate includes dual-acting broad-spectrum immunomodulator EOM613, which has the potential to treat cancer cachexia and rheumatoid arthritis, and its advanced formulation of EOM147 is being studied to treat serious retinal diseases without the need for intraocular injection.

ImmunoCellular Therapeutics (FRA:KOL1) Headlines

No Headlines